The partnership will strategically help the capabilities in rare diseases from research to commercialization, and it will highlight further new opportunities for the rare diseases community. Check the full article here.
Social responsibility is an order nowadays. The social responsibility of companies working with orphan diseases will be discussed by Theresa Heggie, Senior Vice President, Global Commercial Operations at Shire at the Orphan Drug Congress USA, this April.
This forum brings together leading pharma and biotech executives to strategize about the opportunities and challenges in commercializing treatments for rare and ultra-rare diseases. Learn how to market your orphan drugs efficiently, get easier access to your niche and widespread patients, complete pre-clinical and clinical trials with a very widespread patient group, gain market approval from the US FDA, and raise capital and get funding.